Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.

Kaddare S, Bestha RM, Veerla N, Madipelli K, Zakkula A, Dittakavi S, Mullangi R

Open source

DOI
10.1055/a-2877-4153
Published
2026 Sep
Container
Drug research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1055/a-2877-4153,
  title = {Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.},
  author = {Kaddare S and Bestha RM and Veerla N and Madipelli K and Zakkula A and Dittakavi S and Mullangi R},
  year = {2026},
  journal = {Drug research},
  doi = {10.1055/a-2877-4153},
  url = {https://doi.org/10.1055/a-2877-4153}
}

RIS

TY  - JOUR
TI  - Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.
AU  - Kaddare S
AU  - Bestha RM
AU  - Veerla N
AU  - Madipelli K
AU  - Zakkula A
AU  - Dittakavi S
AU  - Mullangi R
PY  - 2026
JO  - Drug research
DO  - 10.1055/a-2877-4153
UR  - https://doi.org/10.1055/a-2877-4153
ER  - 

APA

S, K., RM, B., N, V., K, M., A, Z., S, D., & R, M. (2026). Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor.. Drug research. https://doi.org/10.1055/a-2877-4153

Source records